Serum Adenosine Deaminase as a Useful Marker to Estimate Coronary Artery Calcification in Type 2 Diabetes Mellitus Patients

Yu, Miao; Zhou, Hanyun; Li, Qingan; Ding, Juan; Shuai, Hongxia; Zhang, Ji

doi:10.1177/1076029621999722

Cited by 7 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, we observed that serum ADA levels were significantly positively correlated with CRP levels, ESR, Fg levels and D-dimer levels. Similar to our study, Yu et al ( 22 ) also found that serum ADA levels were positively correlated with CRP levels in patients with T2D. ADA is most abundantly expressed in lymphoid tissues and is indispensable for regulating the proliferation and differentiation of T lymphocytes and the maturation and function of monocytes and macrophages ( 23 ).…”

Section: Discussionsupporting

confidence: 90%

Serum adenosine deaminase levels are associated with diabetic kidney disease in type 2 diabetic patients

Liu

et al. 2021

Endocrine Connections

View full text Add to dashboard Cite

The aim of the present study was to evaluate the association between adenosine deaminase (ADA) levels and diabetic kidney disease (DKD) in patients with type 2 diabetes (T2D). In this study, patients with T2D who had been screened for DKD were recruited. Patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2 or a urinary albumin-to-creatinine ratio (UACR) ≥ 30 mg/g for 3 months were identified as having DKD. The prevalence of DKD was 13.3%, and the range of serum ADA levels was 4-37 U/L. Serum ADA levels were positively associated with cystatin C levels and UACR (r = 0.295 and r = 0.302, respectively, both p < 0.05) and negatively associated with eGFR (r = -0.342, p < 0.05). The proportion of participants with DKD increased significantly from 3.8% in the first tertile (T1) to 13.6% in the second tertile (T2) and 25.9% in the third tertile (T3) of ADA (p for trend < 0.001). After adjusting for clinical risk factors for DKD via multiple logistic regression, the corresponding odds ratios (ORs) of DKD for the participants in T2 and T3 versus those in T1 of ADA were 5.123 (1.282–20.474) and 10.098 (1.660–61.431), respectively. Receiver operating characteristic (ROC) analysis revealed that the optimal cutoff value of ADA to indicate DKD was 10 U/L. Its corresponding sensitivity and specificity were 75.5% and 56.4%, respectively. Our results demonstrated that serum ADA levels were closely associated with DKD and partly reflect the risk of DKD in patients with T2D.

show abstract

Section: Discussionsupporting

confidence: 90%

Serum adenosine deaminase levels are associated with diabetic kidney disease in type 2 diabetic patients

Liu

et al. 2021

Endocrine Connections

View full text Add to dashboard Cite

show abstract

“…Moreover, serum ADA levels were also found to be elevated in inflammatory diseases, such as ectopic pregnancy, gestational diabetes mellitus, preeclampsia, and inflammatory bowel disease ( 31 – 34 ). In addition, patients with increased cardiometabolic risks are always characterized by elevated serum ADA levels, and these cardiometabolic risks include higher BMI ( 35 ), increased TC ( 36 ), hypertension ( 16 ), atherosclerosis ( 13 ), thrombosis ( 14 ), coronary artery calcification ( 37 ) and T2D ( 38 ). Furthermore, in our previous studies and other previous studies, elevated serum ADA levels are not only involved in impaired pancreatic β-cell function in T2D ( 39 ) but also contribute to several diabetic complications, such as diabetic retinopathy ( 40 ), diabetic nephropathy ( 41 ), and prolonged heart QT interval in T2D ( 42 ).…”

Section: Discussionmentioning

confidence: 99%

Increased levels of serum adenosine deaminase and increased risk of diabetic peripheral neuropathy in type 2 diabetes

Zhuang

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundIncreased serum adenosine deaminase (ADA) levels have been shown to be involved in metabolic abnormalities and immune disequilibrium, which may in turn contribute to inflammatory diseases. This study aimed to determine whether increased serum ADA levels are related to diabetic peripheral neuropathy (DPN) in patients with type 2 diabetes (T2D).MethodsThis study was part of a series exploring the potential risks for DPN. All patients received DPN assessment based on neuropathic symptoms, neuropathic signs, and nerve conduction studies to calculate the composite Z score of nerve latency, amplitude and conduction velocity (NCV). DPN was confirmed by both at least a presentation of neuropathic symptoms/signs and an abnormal nerve conduction index. Serum ADA levels were also synchronously detected.ResultsA total of 384 eligible patients with T2D were recruited for this study, and 24.5% (n=94) were determined to have DPN. Increases in serum ADA levels were closely associated with increases in composite Z score of latency (β=0.263, t=5.273, p<0.001) and decreases in composite Z score of amplitude (β=–0.126, t=–2.352, p=0.019) and NCV (β=–0.201, t=–3.841, p<0.001) after adjusting for other clinical covariates. Moreover, each 5 U/L increase in serum ADA levels was associated with a 1.781-fold increased adjusted odds ratio of having DPN (95% confidence interval: 1.271–2.495). Furthermore, the optimal cut-off value of serum ADA levels to discriminate DPN was ≥14.2 U/L (sensitivity=59.57%, specificity=75.52% and Youden index=0.351) after analysis by receiver operating characteristic curve.ConclusionsIncreased serum ADA levels may be a potential risk factor for DPN in patients with T2D.

show abstract

“…The expression of ADA is significantly increased in tissues rich in macrophage in a rat model of fecal peritonitis ( 24 ). Yu et al revealed that in patients with T2D, serum ADA levels were positively associated with C-reactive protein (CRP) and could be a useful marker to assess the severity of atherosclerosis ( 14 ). In our previous study, serum ADA levels were significantly associated with evaluation indexes of diabetic kidney disease (DKD), such as UACR, cystatin C and eGFR, and potentially were an important risk factor for DKD.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, elevated serum ADA levels in T2D may be associated with myocardial ischemia. Coincidentally, Yu et al have found that serum ADA levels are associated with the severity of atherosclerosis ( 14 ). A cross-sectional study of 501 patients with T2D exhibits that hyperglycemia and myocardial ischemia are important contributors to prolonged QTc ( 15 ).…”

Section: Introductionmentioning

confidence: 99%

The relationship between adenosine deaminase and heart rate-corrected QT interval in type 2 diabetic patients

et al. 2021

Endocrine Connections

View full text Add to dashboard Cite

Background: Prolonged heart rate-corrected QT (QTc) interval may reflect poor prognosis of patients with type 2 diabetes (T2D). Serum adenosine deaminase (ADA) levels are related to hyperglycemia, insulin resistance (IR) and inflammation, which may participate in diabetic complications. We investigated the association of serum ADA levels with prolonged QTc interval in a large-scale sample of patients with T2D. Methods: In this cross-sectional study, a total of 492 patients with T2D were recruited. Serum ADA levels were determined by venous blood during fasting. QTc interval was estimated from resting 12-lead electrocardiograms, and prolonged QTc interval was defined as QTc > 440 ms. Results: In this study, the prevalence of prolonged QTc interval was 22.8%. Serum ADA levels were positively associated with QTc interval (r = 0.324, p < 0.0001). The proportion of participants with prolonged QTc interval increased significantly from 9.2% in the first tertile (T1) to 24.7% in the second tertile (T2) and 39.0% in the third tertile (T3) of ADA (p for trend <0.001). After adjusting for other possible risk factors by multiple linear regression analysis, serum ADA level was still significantly associated with QTc interval (β = 0.217, t = 3.400, p < 0.01). Multivariate logistic regression analysis showed that female (OR 5.084, CI 2.379-10.864, p < 0.001), insulin-sensitizers treatment (OR 4.229, CI 1.290-13.860, p = 0.017) and ADA (OR 1.212, CI 1.094-1.343, p < 0.001) were independent contributors to prolonged QTc interval. Conclusions: Serum ADA levels were independently associated with prolonged QTc interval in patients with T2D.

show abstract

Serum Adenosine Deaminase as a Useful Marker to Estimate Coronary Artery Calcification in Type 2 Diabetes Mellitus Patients

Cited by 7 publications

References 32 publications

Serum adenosine deaminase levels are associated with diabetic kidney disease in type 2 diabetic patients

Serum adenosine deaminase levels are associated with diabetic kidney disease in type 2 diabetic patients

Increased levels of serum adenosine deaminase and increased risk of diabetic peripheral neuropathy in type 2 diabetes

The relationship between adenosine deaminase and heart rate-corrected QT interval in type 2 diabetic patients

Contact Info

Product

Resources

About